This section of the website is for patients who have been prescribed Cabometyx® (cabozantinib) in Ireland. Information for members of the general public can be found here.
Side effects reporting information is available at the bottom of this webpage.

Understanding Your Cancer

Understanding Your Cancer

Receiving a diagnosis of cancer can feel overwhelming, so it’s important that you understand your condition. In this section, you can learn more about advanced kidney cancer (advanced renal cell carcinoma) using the information and overview video.

WHAT IS KIDNEY CANCER?1

The kidneys are two organs that are part of the urinary system. The kidneys filter blood to remove excess water and waste substances. These waste products are then made into urine.

Kidney cancer usually only affects one kidney. It is very uncommon for cancer to be in both kidneys.

WHAT IS KIDNEY CANCER?<sup>1</sup>

TYPES OF KIDNEY CANCER1

Renal cell cancers

There are different types of kidney cancer. Around 80% of kidney cancers are renal cell cancers (RCC), which start in the cortex of the kidney.

There are various types of RCC. The most common type is clear cell renal cancer.

Some of the less common types include:

  • Papillary renal cell cancer
  • Chromophobe renal cell cancer

 

Other types of kidney cancer:

Kidney cancer can also start in the ureter and renal pelvis, although this is rare. If the cancer starts in the renal pelvis, this is usually a type of cancer called urothelial cancer or transitional cell carcinoma.

Another rare type of kidney cancer is collecting duct cancer (CDC). This cancer has features of both RCC and of urothelial cancer.

TYPES OF KIDNEY CANCER<sup>1</sup>

UNDERSTANDING KIDNEY CANCER AND YOUR TREATMENT

This video provides an introduction to kidney cancer and gives an overview of treatment with Cabometyx®.

UNDERSTANDING KIDNEY CANCER AND YOUR TREATMENT

Reference:

  1. Kidney cancer. Macmillan Cancer Support. November 2021. Available at: www.macmillan.org.uk/cancer-information-and-support/kidney-cancer (Accessed: October 2023).

For further information, please refer to the Patient Information Leaflet provided with your medicine.

To access relevant information about Renal Cell Carcinoma, please choose one of the following options:

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.